• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 7
  3. Authors

Online ISSN: 2515-8260

Volume7, Issue7

Design, Synthesis, Biological And In Silico Evaluation Of Phenylene (Bis) Hydrazone Derivatives Against Osteosarcoma Cancer

    Pilli Govindaiah Rakesh Kumar Praveen Kumar Guttula Mukesh Kumar Gupta Jaya Prakash M

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 2617-2632

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Three sets of differentphenylene-bis(hydrazone) derivatives namely,Gc, Gd and Ge,were designed, synthesized and evaluated for their molecular properties andin vitro anticancer activity against human osteosarcoma MG-63 cells. All compounds showed potent anticancer activity against the MG63 cells with IC50ranging from 18.27 to 21.68μM. Among three sets of compounds,Ge showed the most potent anticancer activity against osteosarcoma MG63 cells and was superior to standard anticancer reference drug,methotrexate (MTX). All compounds were characterized by spectroscopic studies (FT-IR, 1H NMR, and13C NMR). In silicomolecular properties and drug-like properties were predicted by using Osiris property explorer software. None of Gc and Ge set of compounds violated Lipinski’s boundaries thereby suggesting good oral bioavailability. All the synthesized compounds possessed good pharmacokinetic properties in terms of absorption, distribution, metabolism and toxicity (ADMET). However, the GdSeries compoundswere predicted to be capableof crossing BBB due to their high lipophilicity. The Gc and Ge series of compounds showed good pharmacokinetic parameters within the acceptable range. All the synthesized drugs were predicted to have better pharmacokinetic properties thanthe MTX reference drug.Taken together, our study suggests that Ge series derivatives may be considered as lead drug molecules for possible anticancer applications to be useful against osteosarcoma.
Keywords:
    Hydrazone In silico Molecular properties osteosarcoma cytotoxicity
  • PDF (897 K)
  • XML
(2020). Design, Synthesis, Biological And In Silico Evaluation Of Phenylene (Bis) Hydrazone Derivatives Against Osteosarcoma Cancer. European Journal of Molecular & Clinical Medicine, 7(7), 2617-2632.
Pilli Govindaiah; Rakesh Kumar; Praveen Kumar Guttula; Mukesh Kumar Gupta; Jaya Prakash M. "Design, Synthesis, Biological And In Silico Evaluation Of Phenylene (Bis) Hydrazone Derivatives Against Osteosarcoma Cancer". European Journal of Molecular & Clinical Medicine, 7, 7, 2020, 2617-2632.
(2020). 'Design, Synthesis, Biological And In Silico Evaluation Of Phenylene (Bis) Hydrazone Derivatives Against Osteosarcoma Cancer', European Journal of Molecular & Clinical Medicine, 7(7), pp. 2617-2632.
Design, Synthesis, Biological And In Silico Evaluation Of Phenylene (Bis) Hydrazone Derivatives Against Osteosarcoma Cancer. European Journal of Molecular & Clinical Medicine, 2020; 7(7): 2617-2632.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 213
  • PDF Download: 320
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus